Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:15 PM
Ignite Modification Date:
2026-03-26 @ 3:15 PM
NCT ID:
NCT07320950
Eligibility Criteria:
Inclusion Criteria:
* 18 to 75 years old
* Stage II or III colorectal cancer patients confirmed by pathological diagnosis, and recovered from surgery within 8 weeks
* should receive adjuvant chemotherapy especially XELOX regimen after assessment by physicians and specialists
* Agreed and assigned the consent, and was able to receive the baseline assessment
* Could be inpatient or outpatient participants
Exclusion Criteria:
* Peripheral neuropathy patients, e.g. diabetes neuropathy
* Alcoholic related patients
* Central neuropathy patients
* Patients who were unable to assess the effectivity and safety
* Neurotropin allergy
* History of medications that are contraindicated to neurotropin \<28 days before the trial begins
* Have already received neurotropin tablets more than 4 tablets or 3.6 units \<4 weeks before the trials begins
* Unable to visit the hospital regularly
* Has been ruled out by investigators
* Brain tumor or metastasis
* Brain injury, stroke and brain hemorrhage symptoms occurred during 6 months after sign the consent
* History of epilepsy, convulsion
* Severe respiratory, cardiovascular, renal, hepatic or hematologic system(except cancer) disease
* Depression and other psychologic conditions which investigators recognized as high risk for the enrollment
* Chronic pain
* Received other medication from other clinical trials within 28 days
* Prepare for pregnancy, pregnant, or lactated women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT07320950
Study Brief:
Protocol Section:
NCT07320950